• We rarely use genetic testing while treating first-episode psychosis, as there are no directly relevant genetic tests for diagnosis or treatment selection
  • One specific situation where genetic testing may help is when we face the issue of poor response to treatment or high sensitivity to adverse effects.
  • In a hypothetical case report led by Theo Korchia, a clinical research fellow from Marseille working currently at Montreal-PEPP team, we present a scenario where pharmacogenetics may be of use.
  • These considerations may be particularly relevant when treating early phases of psychosis with aripiprazole or risperidone